Literature DB >> 26515917

The burden of early-onset sepsis in Emilia-Romagna (Italy): a 4-year, population-based study.

Alberto Berardi1, Lorenza Baroni2, Maria Letizia Bacchi Reggiani3, Simone Ambretti4, Giacomo Biasucci5, Serenella Bolognesi6, Maria Grazia Capretti7, Edoardo Carretto8, Matilde Ciccia9, Valentina Fiorini10, Cinzia Fortini11, Giancarlo Gargano2, Maria Federica Pedna12, Vittoria Rizzo13, Roberta Creti14, Fabrizio Ferrari1.   

Abstract

OBJECTIVE: To provide the first Italian data on pathogens causing early-onset sepsis (EOS) and their antimicrobial susceptibility, after the successfully prevention of Group B streptococcus (GBS) EOS.
METHODS: Retrospective area-based cohort study from Emilia-Romagna (Italy). Cases of EOS registered (from 2009 to 2012) in all gestational age neonates were reviewed.
RESULTS: Live births (LB) numbered 146 682. Ninety neonates had EOS and 12 died (incidence rates of 0.61 and 0.08/1000 LB, respectively). EOS and mortality were the highest among neonates with a birth weight <1000 g (20.37/1000 LB and 8.49/1000 LB, respectively). The most common pathogens were GBS (n = 27, 0.18/1000 LB) and Escherichia coli (n = 19, 0.13/1000 LB). Most infants affected by E. coli EOS were born preterm (n = 13), had complications (n = 4) or died (n = 7). Among 90 isolates tested, only 3 were resistant to both first line empirical antibiotics. Multivariate logistic regression analysis showed that low gestational age, caesarean section and low platelet count at presentation were significantly associated with death or brain lesions (area under ROC curve = 0.939, H-L = 0.944, sensitivity 76.0%, specificity 90.7%).
CONCLUSIONS: GBS slightly exceeds E. coli as a cause of EOS. However, E. coli is the prominent cause of death, complications and in most cases affects preterm neonates. Empirical antimicrobial therapy of EOS seems appropriate.

Entities:  

Keywords:  Early-onset sepsis; group B streptococcus; intrapartum chemoprophylaxis; meningitis; newborn infant

Mesh:

Substances:

Year:  2016        PMID: 26515917     DOI: 10.3109/14767058.2015.1114093

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  10 in total

1.  Strategies for preventing group B streptococcal infections in newborns: a nation-wide survey of Italian policies.

Authors:  Chryssoula Tzialla; Alberto Berardi; Claudio Farina; Pierangelo Clerici; Alessandro Borghesi; Elsa Viora; Paolo Scollo; Mauro Stronati
Journal:  Ital J Pediatr       Date:  2017-11-02       Impact factor: 2.638

2.  Contemporary Trends in Global Mortality of Sepsis Among Young Infants Less Than 90 Days: A Systematic Review and Meta-Analysis.

Authors:  Ming Ying Gan; Wen Li Lee; Bei Jun Yap; Shu Ting Tammie Seethor; Rachel G Greenberg; Jen Heng Pek; Bobby Tan; Christoph Paul Vincent Hornik; Jan Hau Lee; Shu-Ling Chong
Journal:  Front Pediatr       Date:  2022-06-03       Impact factor: 3.569

3.  Secondary prevention of early-onset sepsis: a less invasive Italian approach for managing neonates at risk.

Authors:  Alberto Berardi; Chryssoula Tzialla; Laura Travan; Jenny Bua; Daniele Santori; Milena Azzalli; Caterina Spada; Laura Lucaccioni
Journal:  Ital J Pediatr       Date:  2018-06-28       Impact factor: 2.638

4.  Group B Streptococcus early-onset disease and observation of well-appearing newborns.

Authors:  Alberto Berardi; Caterina Spada; Maria Letizia Bacchi Reggiani; Roberta Creti; Lorenza Baroni; Maria Grazia Capretti; Matilde Ciccia; Valentina Fiorini; Lucia Gambini; Giancarlo Gargano; Irene Papa; Giancarlo Piccinini; Vittoria Rizzo; Fabrizio Sandri; Laura Lucaccioni
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

5.  Antibiotic Use in Very Low Birth Weight Neonates After an Antimicrobial Stewardship Program.

Authors:  Alberto Berardi; Isotta Zinani; Cecilia Rossi; Eugenio Spaggiari; Virginia D'Amico; Greta Toni; Luca Bedetti; Laura Lucaccioni; Lorenzo Iughetti; Licia Lugli
Journal:  Antibiotics (Basel)       Date:  2021-04-09

6.  Should we give antibiotics to neonates with mild non-progressive symptoms? A comparison of serial clinical observation and the neonatal sepsis risk calculator.

Authors:  Alberto Berardi; Isotta Zinani; Luca Bedetti; Eleonora Vaccina; Alessandra Toschi; Greta Toni; Marco Lecis; Federica Leone; Francesca Monari; Michela Cozzolino; Tommaso Zini; Alessandra Boncompagni; Lorenzo Iughetti; Francesca Miselli; Licia Lugli
Journal:  Front Pediatr       Date:  2022-07-22       Impact factor: 3.569

Review 7.  Neonatal septic shock, a focus on first line interventions.

Authors:  Valentina Spaggiari; Erica Passini; Sara Crestani; Maria Federica Roversi; Luca Bedetti; Katia Rossi; Laura Lucaccioni; Cecilia Baraldi; Elisa Della Casa Muttini; Licia Lugli; Lorenzo Iughetti; Alberto Berardi
Journal:  Acta Biomed       Date:  2022-07-01

Review 8.  Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-analyses.

Authors:  Lola Madrid; Anna C Seale; Maya Kohli-Lynch; Karen M Edmond; Joy E Lawn; Paul T Heath; Shabir A Madhi; Carol J Baker; Linda Bartlett; Clare Cutland; Michael G Gravett; Margaret Ip; Kirsty Le Doare; Craig E Rubens; Samir K Saha; Ajoke Sobanjo-Ter Meulen; Johan Vekemans; Stephanie Schrag
Journal:  Clin Infect Dis       Date:  2017-11-06       Impact factor: 20.999

9.  Epidemiology and complications of late-onset sepsis: an Italian area-based study.

Authors:  Alberto Berardi; Francesca Sforza; Lorenza Baroni; Caterina Spada; Simone Ambretti; Giacomo Biasucci; Serenella Bolognesi; Mariagrazia Capretti; Edoardo Carretto; Matilde Ciccia; Marcello Lanari; Maria Federica Pedna; Vittoria Rizzo; Claudia Venturelli; Crisoula Tzialla; Laura Lucaccioni; Maria Letizia Bacchi Reggiani
Journal:  PLoS One       Date:  2019-11-22       Impact factor: 3.240

10.  Invasive Group B Streptococcal Disease in Neonates and Infants, Italy, Years 2015-2019.

Authors:  Roberta Creti; Monica Imperi; Alberto Berardi; Erika Lindh; Giovanna Alfarone; Marco Pataracchia; Simona Recchia
Journal:  Microorganisms       Date:  2021-12-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.